Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineXSWX:SHLTN -0.93%52 3-1 Month Momentum % is 17.58% as of Sep. 14, 2026. GuruFocus rates XSWX:SHLTN with a GF Score™ of 52/100 and a GF Value™ of CHF2.63 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 670 Healthcare Providers & Services companies, SHL Telemedicine ranks better than 82.84% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-14), SHL Telemedicine's 3-1 Month Momentum % is 17.58%.
The industry rank for SHL Telemedicine's 3-1 Month Momentum % or its related term are showing as below:
XSWX:SHLTN's 3-1 Month Momentum % is ranked better than 82.84% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 1.805
vs XSWX:SHLTN: 17.58
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
SHL Telemedicine 3-1 Month Momentum % Related Terms
XSWX:SHLTN vs VEEV, BTSG, TEM: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, SHL Telemedicine's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHL Telemedicine (XSWX:SHLTN) has a 3-1 Month Momentum % of 17.58% as of Sep. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SHL Telemedicine and its competitors. According to the industry distribution chart, SHL Telemedicine ranks #115 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 17.2%.
Is SHL Telemedicine's 3-1 Month Momentum % too high?
SHL Telemedicine's current 3-1 Month Momentum % is 17.58%. The Healthcare Providers & Services industry median 3-1 Month Momentum % is 1.81. SHL Telemedicine's value of 17.58% is 874% above this industry median. Based on the distribution chart, SHL Telemedicine ranks #115 out of 670 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, SHL Telemedicine has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's 3-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #115 out of 670 companies for 3-1 Month Momentum %. This places SHL Telemedicine in the top 17% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.81. SHL Telemedicine's value of 17.58% is 874% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
The median 3-1 Month Momentum % among Healthcare Providers & Services companies is 1.81, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SHL Telemedicine's current 3-1 Month Momentum % of 17.58% is 874% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SHL Telemedicine and its competitors. For the Healthcare Providers & Services industry, the median 3-1 Month Momentum % is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current 3-1 Month Momentum % is 17.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
Based on GuruFocus' analysis, SHL Telemedicine (XSWX:SHLTN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF2.63, compared to a current price of CHF1.07 — trading 59.3% below its estimated fair value. The current 3-1 Month Momentum % is 17.58% and 874% above the Healthcare Providers & Services industry median of 1.81. SHL Telemedicine's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For SHL Telemedicine (XSWX:SHLTN), the current 3-1 Month Momentum % is 17.58% as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (XSWX:SHLTN) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of CHF1.07 is trading 59.3% below its estimated GF Value™ of CHF2.63.
GuruFocus considers SHL Telemedicine to be Possible Value Trap.
Key valuation signals for XSWX:SHLTN:
3-1 Month Momentum %: 17.58%
GF Value™: CHF2.63 vs. price of CHF1.07 (59.3% below fair value)
Industry Position: 874% above the Healthcare Providers & Services median (#115 of 670)
No single metric tells the full story. See the XSWX:SHLTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score
Get the complete analysis for XSWX:SHLTN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SHLTN has been successfully added to your 
